Loading
Loading…
Loading…
| # | Company | Amount | Rank | Status |
|---|---|---|---|---|
| 1 | H1₹47.73Admitted-Finance | ₹47.73 | H1 | Admitted-Finance |
| 2 | H2₹41.20−₹6.53 (13.7%)Admitted-Finance | ₹41.20−₹6.53 (13.7%) | H2 | Admitted-Finance |
| 3 | H3₹40.02−₹7.71 (16.2%)Admitted-Finance | ₹40.02−₹7.71 (16.2%) | H3 | Admitted-Finance |
| 4 | H4₹7.46−₹40.27 (84.4%)Admitted-Finance | ₹7.46−₹40.27 (84.4%) | H4 | Admitted-Finance |
| Sl No | Description | Qty | Unit | CENTURION LABORATORIES PVT.LTD H4 | Mylan Laboratories Limited H3 | HETERO LABS LIMITED H2 | NATCO PHARMA LIMITED H1 |
|---|---|---|---|---|---|---|---|
| 1.00ANTI TB DRUGS | |||||||
| 1.01 | Sofosbuvir 400mg | 45,51,120 | Tablets | - | 29.95 ₹33.54 Lowest | 30.89 ₹34.6 | 33.98 ₹38.06 |
| 1.02 | Daclatasvir 60mg | 45,51,120 | Tablets | 6.66 ₹7.46 | 5.78 ₹6.47 Lowest | 5.89 ₹6.6 | 8.64 ₹9.68 |
Tender Value
Refer Docs
EMD Value
₹3.4 L
Closing Date
10 Oct 2023, 3:00 pmClosed
DG and CEO
CMSS New Delhi
Tender for Procurement of Sofosbuvir 400mg and daclatasvir 60mg for NVHCP
2023_CMSS_771268_1
CMSS/PROC/2023-24/NVHCP/040
Open Tender
Drugs and Pharmaceutical Products
Item Rate
60 days
CMSS New Delhi
As per Tender Documents
2 documents required · 2 mandatory
₹0
₹3.4 L
Yes
CMSS New Delhi
17 Nov 2023
12 Sept 2023
11 Oct 2023
12 Sept 2023
10 Oct 2023
25 Sept 2023
12 Sept 2023 - 19 Sept 2023
19 Sept 2023
ANTI TB DRUGS
Sofosbuvir 400mg
Daclatasvir 60mg
HETERO LABS LIMITED
Mylan Laboratories Limited
CENTURION LABORATORIES PVT.LTD
2. Annexure IB
stage.html
html • 0.03 MB
tech_bid_open.pdf
tech_eval.pdf
fin_bid_open.pdf
boq_comp_chart.xlsx
xlsx
Tap a document below to read it instantly. You can also download everything as a ZIP if you prefer.
details.html
html • 0.03 MB
Download all tender documents and submit your bid
Disclaimer: TenderKart has made every reasonable effort to ensure that the information on this page is accurate and authentic, however it cannot be held liable for any third-party claims or losses or any damages. TenderKart makes no warranty, expressed or implied, as to the results obtained from the use of this information. If you notice any error or omission, please let us know at .